Cala Joins the 10th Annual Elizabeth Dole Foundation Convening in Support of Military and Veteran Caregivers

SAN MATEO, Calif., May 20, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, joins the Elizabeth Dole Foundation in Washington, D.C. today for its 10th Annual Convening, A Blueprint for Action:  Mapping the Future of Caregiving in a Changing World.  This milestone event brings together leaders and advocates from communities across the country to build a stronger future for military and veteran caregivers, their veterans, families, and survivors.

Cala is a proud sponsor of the Convening, partnering to bring greater awareness of the benefits of Cala TAPS^™ Therapy for members of the community who struggle and are burdened with managing essential daily activities such as eating, drinking, writing and self-care due to hand tremor.  Thousands of veterans and their families have benefited from the Cala kIQ^™ System, the only FDA cleared wrist-worn neuromodulation device delivering non-invasive TAPS therapy for effective relief of action hand tremor in essential tremor (ET) and Parkinson's (PD) patients.  By empowering veterans to regain independence with everyday tasks, Cala also empowers and supports their caregivers. 

"We are so honored to partner with the Elizabeth Dole Foundation and participate in the 10th Annual Convening," said Deanna Harshbarger, Chief Executive Officer, Cala Health. "It is exciting to see what's possible when we come together to support those who have served, their caregivers, families and survivors."

ET and PD impacts over 7 million people in the United States and is characterized by uncontrollable movement that can make critical daily activities very challenging or even impossible.  Drugs are most used to treat ET, but they can cause a range of unwanted side effects such as fatigue, nausea and depression and may not provide desired outcomes. Surgical options like Deep Brain Stimulation or Focused Ultrasound ablation can be effective but are invasive procedures that carry the risk of potentially irreversible side effects.

The Cala kIQ System with TAPS (Transcutaneous Afferent Patterned Stimulation) Therapy is the only non-invasive, FDA-cleared, wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson's disease. The TAPS device is physician-prescribed and clinically proven to safely and effectively reduce action hand tremors. The Cala kIQ device treats tremor by sensing each patient's unique tremor signature and delivering individualized stimulation to the nerves on the wrist that then reach the brain to counteract tremor. 

The Cala System is available through the Veterans Affairs (VA) Health System at no cost to eligible VA beneficiaries and also through Medicare for those who meet Local Coverage Criteria. Cala continues to advocate on behalf of patients with ET and PD to secure additional coverage and reimbursement, including Medicare Advantage and commercial payor plans. 

About Cala®
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies. Cala Health's products are the only FDA-cleared, clinically validated noninvasive devices for the relief of hand tremors, allowing patients with essential tremor to return to the moments that matter. New therapies are under development in neurology, cardiology, and psychiatry. Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. 

The Cala kIQ^™ device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. The Cala kIQ device is indicated to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand following stimulation in adults with Parkinson's disease. The Cala kIQ device delivers Transcutaneous Afferent Patterned Stimulation (TAPS) therapy.

Caution: Federal law restricts this device to sale by or on the order of a physician.  Prior to use, refer to the product labeling for complete product instructions for use, contraindications, warnings, and precautions at https://calahealth.com. 

SOURCE Cala Health